The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Acceleron Pharma Inc | Common Stock | 00434H108 | 53,563 | 1,480,060 | SH | SOLE | 1,480,060 | 0 | 0 | ||
Alimera Sciences Inc | Common Stock | 016259103 | 4,691 | 3,148,355 | SH | SOLE | 3,148,355 | 0 | 0 | ||
Cerulean Pharma Inc | Common Stock | 15708Q105 | 1,505 | 1,437,441 | SH | SOLE | 1,437,441 | 0 | 0 | ||
Pulmatrix Inc | Common Stock | 74584P103 | 2,627 | 1,591,862 | SH | SOLE | 1,591,862 | 0 | 0 |